MAPKAPK2 and HSP27 are downstream effectors of p38 MAP kinase-mediated matrix metalloproteinase type 2 activation and cell invasion in human prostate cancer

L. Xu, S. Chen, Raymond Bergan

Research output: Contribution to journalArticle

147 Citations (Scopus)

Abstract

Although cell invasion is a necessary early step in cancer metastasis, its regulation is not well understood. We have previously shown, in human prostate cancer, that transforming growth factor β (TGFβ)-mediated increases in cell invasion are dependent upon activation of the serine/ threonine kinase, p38 MAP kinase. In the current study, downstream effectors of p38 MAP kinase were sought by first screening for proteins phosphorylated after TGFβ treatment, only in the absence of chemical inhibitors of p38 MAP kinase. This led us to investigate mitogen-activated protein kinase-activated protein kinase 2 (MAPKAPK2), a known substrate of p38 MAP kinase, as well as heat-shock protein 27 (HSP27), a known substrate of MAPKAPK2, in both PC3 and PC3-M human prostate cells. After transient transfection, wildtype MAPKAPK2 and HSP27 both increased TGFβ-mediated matrix metalloproteinase type 2 (MMP-2) activity, as well as cell invasion, which in turn was inhibited by SB203580, an inhibitor of p38 MAP kinase. Conversely, dominant-negative MAPKAPK2 blocked phosphorylation of HSP27, whereas dominant-negative MAPKAPK2 or mutant, non-phosphorylateable, HSP27 each blocked TGFβ-mediated increases in MMP-2, as well as cell invasion. Similarly, knock down of MAPKAPK2, HSP27 or both together, by siRNA, also blocked TGFβ-mediated cell invasion. This study demonstrates that both MAPKAPK2 and HSP27 are necessary for TGFβ-mediated increases in MMP-2 and cell invasion in human prostate cancer.

Original languageEnglish (US)
Pages (from-to)2987-2998
Number of pages12
JournalOncogene
Volume25
Issue number21
DOIs
StatePublished - May 18 2006
Externally publishedYes

Fingerprint

HSP27 Heat-Shock Proteins
Matrix Metalloproteinase 2
p38 Mitogen-Activated Protein Kinases
Mitogen-Activated Protein Kinases
Protein Kinases
Transforming Growth Factors
Prostatic Neoplasms
Protein-Serine-Threonine Kinases
Mitogen-Activated Protein Kinase Kinases
Small Interfering RNA
Transfection
Prostate
Phosphorylation
Neoplasm Metastasis

Keywords

  • Heat-shock protein 27
  • Invasion
  • Matrix metalloproteinase-2
  • Mitogen-activated protein kinase-activated protein kinase 2
  • Prostate cancer
  • Transforming growth factor β

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Genetics

Cite this

@article{b4f395d5025c49c7bc5456c3abde03b1,
title = "MAPKAPK2 and HSP27 are downstream effectors of p38 MAP kinase-mediated matrix metalloproteinase type 2 activation and cell invasion in human prostate cancer",
abstract = "Although cell invasion is a necessary early step in cancer metastasis, its regulation is not well understood. We have previously shown, in human prostate cancer, that transforming growth factor β (TGFβ)-mediated increases in cell invasion are dependent upon activation of the serine/ threonine kinase, p38 MAP kinase. In the current study, downstream effectors of p38 MAP kinase were sought by first screening for proteins phosphorylated after TGFβ treatment, only in the absence of chemical inhibitors of p38 MAP kinase. This led us to investigate mitogen-activated protein kinase-activated protein kinase 2 (MAPKAPK2), a known substrate of p38 MAP kinase, as well as heat-shock protein 27 (HSP27), a known substrate of MAPKAPK2, in both PC3 and PC3-M human prostate cells. After transient transfection, wildtype MAPKAPK2 and HSP27 both increased TGFβ-mediated matrix metalloproteinase type 2 (MMP-2) activity, as well as cell invasion, which in turn was inhibited by SB203580, an inhibitor of p38 MAP kinase. Conversely, dominant-negative MAPKAPK2 blocked phosphorylation of HSP27, whereas dominant-negative MAPKAPK2 or mutant, non-phosphorylateable, HSP27 each blocked TGFβ-mediated increases in MMP-2, as well as cell invasion. Similarly, knock down of MAPKAPK2, HSP27 or both together, by siRNA, also blocked TGFβ-mediated cell invasion. This study demonstrates that both MAPKAPK2 and HSP27 are necessary for TGFβ-mediated increases in MMP-2 and cell invasion in human prostate cancer.",
keywords = "Heat-shock protein 27, Invasion, Matrix metalloproteinase-2, Mitogen-activated protein kinase-activated protein kinase 2, Prostate cancer, Transforming growth factor β",
author = "L. Xu and S. Chen and Raymond Bergan",
year = "2006",
month = "5",
day = "18",
doi = "10.1038/sj.onc.1209337",
language = "English (US)",
volume = "25",
pages = "2987--2998",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "21",

}

TY - JOUR

T1 - MAPKAPK2 and HSP27 are downstream effectors of p38 MAP kinase-mediated matrix metalloproteinase type 2 activation and cell invasion in human prostate cancer

AU - Xu, L.

AU - Chen, S.

AU - Bergan, Raymond

PY - 2006/5/18

Y1 - 2006/5/18

N2 - Although cell invasion is a necessary early step in cancer metastasis, its regulation is not well understood. We have previously shown, in human prostate cancer, that transforming growth factor β (TGFβ)-mediated increases in cell invasion are dependent upon activation of the serine/ threonine kinase, p38 MAP kinase. In the current study, downstream effectors of p38 MAP kinase were sought by first screening for proteins phosphorylated after TGFβ treatment, only in the absence of chemical inhibitors of p38 MAP kinase. This led us to investigate mitogen-activated protein kinase-activated protein kinase 2 (MAPKAPK2), a known substrate of p38 MAP kinase, as well as heat-shock protein 27 (HSP27), a known substrate of MAPKAPK2, in both PC3 and PC3-M human prostate cells. After transient transfection, wildtype MAPKAPK2 and HSP27 both increased TGFβ-mediated matrix metalloproteinase type 2 (MMP-2) activity, as well as cell invasion, which in turn was inhibited by SB203580, an inhibitor of p38 MAP kinase. Conversely, dominant-negative MAPKAPK2 blocked phosphorylation of HSP27, whereas dominant-negative MAPKAPK2 or mutant, non-phosphorylateable, HSP27 each blocked TGFβ-mediated increases in MMP-2, as well as cell invasion. Similarly, knock down of MAPKAPK2, HSP27 or both together, by siRNA, also blocked TGFβ-mediated cell invasion. This study demonstrates that both MAPKAPK2 and HSP27 are necessary for TGFβ-mediated increases in MMP-2 and cell invasion in human prostate cancer.

AB - Although cell invasion is a necessary early step in cancer metastasis, its regulation is not well understood. We have previously shown, in human prostate cancer, that transforming growth factor β (TGFβ)-mediated increases in cell invasion are dependent upon activation of the serine/ threonine kinase, p38 MAP kinase. In the current study, downstream effectors of p38 MAP kinase were sought by first screening for proteins phosphorylated after TGFβ treatment, only in the absence of chemical inhibitors of p38 MAP kinase. This led us to investigate mitogen-activated protein kinase-activated protein kinase 2 (MAPKAPK2), a known substrate of p38 MAP kinase, as well as heat-shock protein 27 (HSP27), a known substrate of MAPKAPK2, in both PC3 and PC3-M human prostate cells. After transient transfection, wildtype MAPKAPK2 and HSP27 both increased TGFβ-mediated matrix metalloproteinase type 2 (MMP-2) activity, as well as cell invasion, which in turn was inhibited by SB203580, an inhibitor of p38 MAP kinase. Conversely, dominant-negative MAPKAPK2 blocked phosphorylation of HSP27, whereas dominant-negative MAPKAPK2 or mutant, non-phosphorylateable, HSP27 each blocked TGFβ-mediated increases in MMP-2, as well as cell invasion. Similarly, knock down of MAPKAPK2, HSP27 or both together, by siRNA, also blocked TGFβ-mediated cell invasion. This study demonstrates that both MAPKAPK2 and HSP27 are necessary for TGFβ-mediated increases in MMP-2 and cell invasion in human prostate cancer.

KW - Heat-shock protein 27

KW - Invasion

KW - Matrix metalloproteinase-2

KW - Mitogen-activated protein kinase-activated protein kinase 2

KW - Prostate cancer

KW - Transforming growth factor β

UR - http://www.scopus.com/inward/record.url?scp=33646859435&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646859435&partnerID=8YFLogxK

U2 - 10.1038/sj.onc.1209337

DO - 10.1038/sj.onc.1209337

M3 - Article

C2 - 16407830

AN - SCOPUS:33646859435

VL - 25

SP - 2987

EP - 2998

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 21

ER -